Abstract
Desmoplastic small round cell tumor (DSRCT) is an ultra-rare sarcoma with limited treatment options. We performed whole-genome/exome, transcriptome, and DNA methylome analysis in 30 refractory DSRCT patients, complemented by (phospho)proteomic profiling in nine, within a nationwide precision oncology program. In eight patients (27%), DSRCT was diagnosed based on molecular profiling. Although all patients had “quiet” genomes, 28 (93%) received 107 molecular-based management recommendations, including assessment of clinical trial eligibility in 17 (57%). Nearly half of recommendations (45%) were based on overexpression of tyrosine kinases, as well as SSTR3/5 and CLDN6, detected in 33% and 20% of cases, respectively. Thirteen patients (46%) received recommended therapies, yielding disease control in eight (62%; partial response, n = 5; stable disease, n = 3), including three long-lasting responses (≥ 12 months) to pazopanib and trastuzumab deruxtecan, triggered by ERBB2 overexpression in the absence of constitutive ERBB2 signaling. Thus, multi-omics profiling enables individualized DSRCT treatment.
Introduction: The Challenge of DSRCT
Desmoplastic Small Round Cell Tumor (DSRCT) is an aggressive, ultra-rare sarcoma that primarily affects children and young adults. Clinically, it is characterized by a "genomically quiet" profile, meaning it possesses a very low mutational burden. This lack of obvious genetic drivers makes identifying therapeutic targets via standard DNA sequencing exceptionally difficult. Furthermore, the tumor's ambiguous histology frequently leads to misdiagnosis, and with no established standard-of-care, most patients face a poor prognosis, often succumbing to the disease within three years.
Methods: A Multi-Layered Molecular Approach
To address these challenges, researchers utilized the MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program, a German nationwide precision oncology platform. The study integrated multiple layers of molecular data from 30 refractory DSRCT patients:
- Whole-Genome/Exome Sequencing (WGS/WES): To identify rare mutations and copy number variants.
- RNA Sequencing (RNA-seq): To detect the pathognomonic EWSR1::WT1 fusion and quantify gene expression levels.
- DNA Methylome Analysis: Using machine-learning classifiers to confirm the tumor's epigenetic signature.
- Proteomics and Phosphoproteomics: Conducted on a subset of nine patients to measure actual protein levels and signaling pathway activity.
Patient Cohort
The study focused on 30 patients with refractory disease. The demographic and clinical characteristics of this cohort are summarized below, highlighting the typical presentation of DSRCT in young, predominantly male patients with intra-abdominal primary tumors.
Key Insights: Beyond DNA Mutations
The multi-omics approach revealed that while the DSRCT genome is indeed "quiet" regarding actionable mutations (only 4% of recommendations were based on single-nucleotide variants), the transcriptome and proteome are rich with information.
Molecular Rediagnosis
In 27% of cases (8 out of 30), the initial diagnosis was corrected or refined. The detection of the EWSR1::WT1 fusion and specific methylation patterns allowed for the accurate reclassification of these tumors as DSRCT, which is critical for determining the correct clinical path.
ERBB2 (HER2) as a "Bystander" Target
A significant finding was the efficacy of Trastuzumab Deruxtecan (T-DXd). Even in the absence of ERBB2 gene amplification or active HER2 signaling, high protein expression on the cell surface allowed this antibody-drug conjugate (ADC) to deliver its cytotoxic payload effectively, leading to long-lasting clinical responses.
Emerging Therapeutic Frontiers
The study identified consistent overexpression of SSTR3/5 and CLDN6. These represent promising targets for peptide receptor radionuclide therapy and emerging CAR T-cell therapies, respectively, offering new hope for clinical trial development in this orphan disease.
Clinical Results and Efficacy
The impact of molecular profiling on patient management was substantial:
- Actionable Recommendations: 93.3% of patients (28/30) received at least one molecularly-based treatment recommendation.
- Disease Control: Of the 13 patients who received the recommended targeted therapies, 62% achieved disease control (5 partial responses and 3 stable disease).
- Durability: The study noted remarkable long-lasting responses (≥ 12 months) to the tyrosine kinase inhibitor pazopanib and the ADC T-DXd, even in patients who had failed multiple prior lines of heavy chemotherapy.
Limitations and Future Directions
Despite the high rate of recommendations, only 46% of patients actually received the suggested treatments, often due to rapid disease progression or difficulties in securing off-label insurance coverage. The authors emphasize that DSRCT diagnostic protocols should, at a minimum, mandate RNA-seq or fusion detection. Furthermore, dedicated clinical trials are needed to validate the use of T-DXd, CLDN6-targeted CAR T-cells, and SSTR-targeted therapies in this specific patient population.
Summary updated